<DOC>
	<DOCNO>NCT00126230</DOCNO>
	<brief_summary>This prospective phase II trial docetaxel-samarium patient hormone-refractory advanced prostate cancer achieve response stabilization docetaxel-estramustine .</brief_summary>
	<brief_title>Trial Docetaxel-Samarium Patients With Hormone-Refractory Advanced Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Estramustine</mesh_term>
	<criteria>Patients older 18 year less 80 year Histologicallyproven adenocarcinoma prostate Evidence bone metastasis progressive , hormonerefractory , disease No previous chemotherapy No previous radiotherapy , except radiotherapy direct prostate and/or single bony lesion No previous carcinoma , except basalcell carcinoma skin Adequate renal function : measure calculated creatinine clearance &gt; 60 ml/min Absolute granulocyte count ≥ 1,500/mm3 , platelet ≥ 100,000 mm3 , bilirubin ≤ 1.5 fold upper normal value Signed informed consent . Patients infected Human Immunodeficiency Virus ( HIV ) Patients fit inclusion criterion</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>hormone-refractory advanced prostate cancer achieve response stabilization docetaxel-estramustine</keyword>
</DOC>